Kolexia
Thieblemont Catherine Oncologie médicale
Thieblemont Catherine
Oncologie médicale
Hôpital Saint-Louis
Paris, France
751 Activités
691 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome B Lymphome B diffus à grandes cellules Lymphome à cellules du manteau Lymphome malin non hodgkinien Maladie de Hodgkin Lymphome B de la zone marginale Lymphome folliculaire Récidive tumorale locale

Collaborateurs

Voir plus
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Tilly Herve
Tilly Herve
Centre Henri-Becquerel, Rouen, France
Salles Gilles
Salles Gilles
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Novartis
35 collaboration(s)
Dernière en 2023
Janssen
31 collaboration(s)
Dernière en 2023
Abbvie
26 collaboration(s)
Dernière en 2023
Celgene
16 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
BELINDA: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Essai Clinique (Novartis)   20 mars 2024
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL): A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Essai Clinique (Celgene)   04 mars 2024
EPCORE™ NHL-1: A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Essai Clinique (Genmab)   04 mars 2024
Emergency department visits after chimeric antigen receptor T cell therapy: a retrospective observational study.
European journal of emergency medicine : official journal of the European Society for Emergency Medicine   27 février 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica   22 février 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   16 février 2024
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse: Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Essai Clinique (The Lymphoma Academic Research Organisation)   14 février 2024
ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Essai Clinique (Gilead)   09 février 2024